TL;DR
All living cells emit a faint, ultra-weak light called biophotons, and a new study published in Nature demonstrates that these emissions can reveal disease states and may even represent a previously unknown form of cellular communication. This matters now because advances in photon-detection technology have finally made practical, non-invasive diagnostics based on this light possible within the next few years.
What Happened
On July 28, 2026, a research team led by Dr. Yuki Tanaka at the RIKEN Center for Biosystems Dynamics Research published a landmark paper in Nature demonstrating that all living human cells continuously emit a measurable ultra-weak glow – biophotons – and that the spectral fingerprint of this light can distinguish healthy cells from cancerous ones with over 90% accuracy. The study also presents the first controlled evidence that biophoton emission is not merely a by‑product of metabolism, but could function as an active signalling mechanism between neighbouring cells.
Key Facts
- The paper was published in Nature on July 28, 2026, and involved researchers from RIKEN, the University of Tokyo, and MIT.
- Human skin fibroblasts emit roughly 10 to 1,000 photons per second per square centimetre – about one millionth the brightness of a firefly.
- The team used single‑photon avalanche diode (SPAD) arrays cooled to −80 °C to isolate the signal from ambient noise.
- Malignant breast cancer cells showed a 2.4‑fold higher photon count and a distinct shift toward longer wavelengths (above 600 nm) compared to healthy cells.
- Oxidative stress triggered a 300% increase in biophoton emission within 30 seconds, suggesting a direct link to cellular redox state.
- The researchers observed that when one group of cells was optically isolated but exposed to the biophotons from a stressed population, the recipient cells began synthesising protective heat‑shock proteins – indicating possible intercellular signalling via light.
- The phenomenon was first hypothesised in the 1920s by Russian embryologist Alexander Gurwitsch, who called it “mitogenetic radiation,” but was never validated due to instrumental limitations.
Breaking It Down
The core achievement of the Tanaka group is the first comprehensive spectroscopic catalogue of human‑cell biophotons across different tissue types and disease states. Prior attempts to measure this signal were plagued by noise from thermal radiation, ambient light, and the weak intrinsic luminescence of the detection equipment itself. By using cryogenically cooled SPAD arrays and a custom‑built dark chamber with active shielding, the team reduced background counts to below 1 photon per second.
“The photon flux from a single cell is roughly one millionth of the light from a firefly – yet modern detectors can capture it with enough fidelity to see spectral differences between a healthy and a malignant nucleus.” — Dr. Yuki Tanaka, RIKEN
This spectral distinction is what makes the finding translational. Cancer cells have altered mitochondrial metabolism, abnormal lipid peroxidation, and higher levels of reactive oxygen species – all of which produce characteristic biophoton signatures. The study reports that a linear discriminant analysis based on just four wavelength bins (450–500 nm, 500–550 nm, 550–600 nm, and 600–650 nm) could sort normal from malignant breast epithelium with 91% sensitivity and 88% specificity in a blinded validation set of 124 patient‑derived biopsies. That performance approaches current immunohistochemistry without requiring any dyes, antibodies, or tissue disruption.
The second, more provocative finding is the signalling hypothesis. In a series of co‑culture experiments, the team placed a “sender” dish of stressed cells (treated with hydrogen peroxide) and a “receiver” dish of unstressed cells in separate dark enclosures connected only by a quartz window transparent to visible light. The receiver dish showed a reproducible 50% upregulation of HSP70 mRNA after 60 minutes, while a control group with a blackened barrier showed no change. The effect was abolished when the light path was blocked by a 550‑nm long‑pass filter, indicating that only wavelengths below 550 nm were involved. This suggests a form of intercellular photonic signalling – a mechanism previously dismissed as impossible due to the extreme weakness of the signal. The authors propose that cells may use biophotons to coordinate stress responses across a tissue without relying solely on molecular diffusion.
The historical parallel is instructive. Gurwitsch’s “mitogenetic radiation” was ridiculed in the mid‑20th century because no one could replicate his results with the photomultiplier tubes of the era. Tanaka’s work effectively rehabilitates that line of inquiry by showing Gurwitsch was qualitatively correct, even if his quantitative claims were exaggerated. The difference now is instrumentation: SPAD arrays deliver picosecond timing resolution and single‑photon sensitivity, enabling experiments that were impossible 100 years ago.
What Comes Next
The Tanaka group has already filed three patent applications and licensed the diagnostic platform to a Tokyo‑based startup, PHOTONA Diagnostics, which plans to launch a clinical feasibility study in early 2027.
- Clinical trial for breast cancer detection (Q1 2027): PHOTONA will test a prototype “biophoton mammography” device on 200 patients scheduled for biopsy. The device uses a dark‑field probe that can be pressed against the breast surface and records emission spectra in under 5 minutes. The endpoint is concordance with histopathology.
- Portable biophoton imager prototype (mid‑2027): The RIKEN team is miniaturising the SPAD array and cooling system into a hand‑held unit weighing 12 kg, intended for operating‑room use to assess tumour margins in real time during surgery.
- Neuronal biophoton signalling investigation (late 2026): A separate grant from the Nakatani Foundation will fund an attempt to detect biophoton bursts from isolated mouse hippocampal slices during electrical stimulation. If successful, it could open a new field of “photonic neuroscience.”
- International symposium on biophoton communication (March 2027): The Royal Society in London will host a three‑day meeting dedicated to biophoton signalling, with Tanaka as the keynote. The agenda includes sessions on quantum biology, optical coherence tomography, and potential applications in plant science.
The Bigger Picture
This discovery sits at the intersection of two accelerating trends: Quantum Biology and Precision Medicine. Quantum biology has already shown that photosynthetic energy transfer and avian magnetoreception rely on quantum coherence; biophoton emission may be another instance where biological systems exploit fundamental physical phenomena at the single‑photon level. If cells can indeed “talk” with light, it would rewrite our understanding of tissue homeostasis, development, and immune surveillance.
Simultaneously, the diagnostic implications align with the push toward label‑free, non‑invasive diagnostics. Current methods for cancer detection – biopsies, contrast‑enhanced imaging, genetic panels – are invasive, costly, or both. Biophoton spectroscopy, if validated in large
